Reduced serum complement levels are well documented in systemic lupus erythematosus (SLE) (Schur and Austen, 1968) , and complement-mediated inflammation is thought to be a pathogenetic mechanism in this disease (Miescher and Paronetto, 1969 ). Variation in the complement level probably reflects the disease activity (Townes, 1967; Schur and Sandson, 1968) and response to treatment (Ruddy, Everson, Schur, and Austen, 1971a) .
Rheumatoid arthritis is a clinically similar disease in which immunological mechanisms are also implicated. However, the significance of complement involvement in this disease has not been as extensively studied. Studies of static serum levels of complement components are not in themselves indicative of complement participation. More direct evidence of complement involvement in rheumatoid arthritis is the presence of IgG-BIC complexes in synovial fluid (Vaughan, Barnett, Sobel, and Jacox, 1968) and synovial cells (Hurd, LoSpalluto, and Ziff, 1969, 1970) . Increased complement consumption has been demonstrated by turnover studies of C3 component using radiolabelled C3 (Weinstein, Peters, Brown, and Bluestone, 1972) and is associated with raised immunoconglutinin levels (Marks and Coombs, 1957; Mustakallio and Kalliomaki, 1968) .
Activation of the complement system and utilization ofcomplement is associated with the production from the parent complement components of smaller fragnents. These fragments-'inactivation products' -retain some of the antigenic characteristics of the parent molecule and cross-react with antisera prepared against the parent molecule, but have a different electrophoretic mobility.
The present investigations were undertaken to see if the individual fragments produced during complement consumption could be demonstrated in rheumatoid arthritis serum and if so to assess their significance and value in following treatment. To enable this to be done, a semi-automated modification of the two-dimensional technique of Clarke and Freeman (1968) was developed. The technique used depends on the identification and measurement of C3 and C4 and their inactivated (converted) components C3i and C4i by immunochemical means, using an oligospecific antiserum. The method has been proven to be sensitive and reproducible.
Materials and methods
All patients were outpatients. Those with rheumatoid arthritis all had classical disease by ARA criteria (Ropes, Bennett, Cobb, Jacox, and Jessar, 1959) . Clinical activity was measured by grip strength and activity index (Ritchie, Boyle, McInnes, Jasani, Dalakos, Grieveson, and Buchanan, 1968 ). Blood samples were taken both at morning and afternoon clinics. The erythrocyte sedimentation rate (ESR) was measured by the Westergren method, using 2 ml. freshly drawn blood and 0-5 ml. 3-8 per cent. sodium citrate, and reading at one hour. Waaler-Rose titres were estimated as a differential agglutination ratio, all sera from a single patient being tested together. Plasma was obtained before gold injections by drawing blood into EDTA tubes, the plasma being stored at -20°C. until used and thawed once at the time of estimation of complement. No sample for complement estimation was used after 3 weeks. Storage at -70°C. is recommended for longer periods.
TREATMENT
Four patients, none of whom showed response to gold therapy, were followed through the course of their trial of treatment with gold, two of these patients were being treated with prednisone (7-5 mg. and 12-5 mg. respectively throughout, the dose of which was kept constant. The patients received sodium aurothiomalate in doses from 20 to 80 mg. intramuscularly at weekly or fortnightly None of the rheumatoid patients or controls had received corticosteroids or gold injections in the preceding 6 months. All the disease controls had active disease but were not on corticosteroid therapy at the time of taking blood samples.
MEASUREMENT OF COMPLEMENT CONVERSION
Using a semi-automated two-dimensional immunoelectrophoretic method previously described (Versey, 1971) , conversion of C3 and C4 was estimated. A single sheep antiserum against human plasma fl-region, with proven reactivity for C3, C4, and transferrin, was used throughout. Area measurements of the resultant peaks are calculated by planimetry, but simple area measurement by the triangular technique results in only slight loss of accuracy (Versey and Slater, 1973) . Transferrin, used as the internal standard, was measured accurately in each plasma sample by rocket electrophoresis (Laurell, 1966) With this anti-human ,8-region serum, no such conversion factor appears necessary, and thus conversion can be expressed directly in mg./100 ml. or in percentage conversion of total C3 or C4. Total C3 and C4 were measured from the two-dimensional plates as the areas of each component plus its converted material.
Results

NORMAL SERA
Normal sera contained uniform peaks of C3 and C4 without continuation as the inactivation products C3i and C4i (Fig. 1) . The transferrin peak used as a standard is clearly seen. The range of C3 and C4 levels is wide in normal individuals (Table I) . Conversion products were rarely found in normal sera and then only to a small extent. In the longitudinal studies little variation in complement levels occurred and conversion products were rarely found in normal individuals. 
However, in both Table I and Figs 2 and 3, sera which showed conversion have been purposely included to emphasize that this may occur to a small degree even in normal people. No significant variation of complement levels with age or sex was found.
RHEUMATOID SERA There was a tendency for the levels of both C3 and C4 to be elevated but with a very wide range of values (Table II, opposite) . However, it was in the presence of conversion products (Fig. 4, Fig. 2 . Note varying baseline these were raised to a greater degree than was found in the normal sera. In the patients' sera the continual variation in all parameters measured was marked and usually unassociated with obvious clinical change (Figs 5, 6, 7, overleaf) . One of the patients (Fig. 5 The pattern of conversion is again slightly different (Fig. 8) tend to be within the normal range (Table III) . (Sliwinski and Zvaifler, 1972) and increased synthesis in rheumatoid arthritis (Weinstein and others, 1972) , decreased catabolism may occur in some patients with rheumatoid arthritis (Alper and Rosen, 1967) .
Elevation of complement level seems to occur in many inflammatory conditions when the disease is active (Vaughan, Bayles, and Favour, 1951; Ellis and Felix-Davies, 1959; Jonsen and Kass, 1961) , presumably because of increased synthesis. This explains the shape of our curves whereby the elevation of complement (C3 or C4) is often associated with increased rates of complement conversion (C3i and C4i), conversion of both C3 or C4 occurring in unison. Conversely, low CH50 levels have been found to be associated with the complications of rheumatoid arthritis (Franco and Schur, 1971) . The opposite effect is found in SLE, where activity and complement conversion is associated with reduced complement levels (Sliwinski and Zvaifler, 1972) .
The spontaneous fluctuation of complement levels during the course of the disease is interesting and has been noted previously (Schubart, Ewald, Schroeder, Rothschild, Bhatavadekar, and Pullen, 1965) . Thus rheumatoid disease, by these immunological parameters, is seen as a variable and even episodic disorder. The current approach may offer a sensitive monitor for disease activity. Ruddy and others (1971a) have shown a good correlation between C9 and the erythrocyte sedimentation rate, less marked correlation of CH50 and Cl with the erythrocyte sedimentation rate, but no correlation between C4 or C2 levels and the erythrocyte sedimentation rate. From the present results, however, it will be obvious that isolated values for complement should not be used in judging the relative severity of the disease in individual patients with rheumatoid arthritis.
The source of the conversion products is not clear. Complement consumption probably indicates active humoural immunity and immune complex formation, and this is made more likely since the C4i and C3i levels fluctuate in parallel, which would not happen if entry by the alternate pathway (Gotze and MullerEberhard, 1971) or non-specific proteolysis was the main route of complement degradation. They may arise either from the inflamed joints or from intravascular sites. In synovial fluid, the presence of lowered complement levels (Ruddy and Austen, 1970; Townes and Sowa, 1970) , together with the greater rate of catabolism of intra-articular compared with intravascularly administered C3 (Ruddy, MullerEberhard, and Austen, 1971b) , suggests that one source of complement degradation products is from the joint. Diffusion of C3i (mol. weight -120,000) across the synovial membrane probably occurs fairly rapidly, since radioactive complement given into the joint is rapidly found in the systemic circulation and larger molecules, e.g. IgM, also move readily across the inflamed synovial membrane. The association of increased C3 catabolism with vasculitis (Weinstein and others, 1972) may reflect either the severity of the disease processes or complement consumption within the circulation, although the latter has not been demonstrated (Douglas, 1965) . In the one patient (Fig. 5) , who developed recurrent vasculitic lesions and nodules during the course of his treatment, no association with the complement pattern was seen.
The interrelations between rheumatoid factors and complement are numerous. Rheumatoid factor levels may simply reflect disease activity or may influence the metabolism ofcomplement. CH50 levels tend to be lower in seropositive than in seronegative patients (Mongan, Cass, Jacox, and Vaughan, 1969) ; moreover, subnormal levels are more often associated with severe disease, particularly vasculitis (Franco and Schur, 1971 ). Systemic catabolic rates are elevated in seropositive but not in seronegative patients, even in the absence ofvasculitis (Ruddy and others, 1971b) . Lowered complement levels in rheumatoid synovial fluid seem to be related to the level of rheumatoid factor present (Hedberg, 1967; Winchester, Agnello, and Kunkel, 1970) . Precipitation of synovial fluid complexes of IgG by IgM rheumatoid factor occurs (Hannestad, 1967 
